ResApp announces FDA 510(k) submission for SleepCheckRx

October 11, 2021

View printer-friendly version ResApp has submitted a 510(k) premarket notification to the US FDA for SleepCheckRx SleepCheckRx is a smartphone-only solution that uses clinically accurate algorithms to assess a patient’s risk of obstructive sleep apnoea by analysing...

First patients recruited in COVID-19 clinical study in India

September 20, 2021

View printer-friendly version First patients recruited in Indian study to collect cough sounds from patients with suspected COVID-19 Study aims to recruit 220 participants, with recruitment expected to be complete by the end of October ResApp aims to use the data to...

ResApp receives Advanced and Overseas R&D finding

September 14, 2021

View printer-friendly version Brisbane, Australia, 14 September 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease is pleased to announce that it has...

ResAppDx receives regulatory approval in Indonesia

September 1, 2021

View printer-friendly version Brisbane, Australia, 1 September 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce receipt of...

Alodokter to launch ResAppDx in Indonesia

August 4, 2021

View printer-friendly version Alodokter is the largest provider of telehealth services in Indonesia Launched in 2014, Alodokter brings high-quality medical services to more than 30 million monthly active users by providing an integrated mobile solution for patients...